Efficacy of Extended-Release Naltrexone in Alcohol-Dependent Patients Who Are Abstinent Before Treatment
- 1 October 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 27 (5), 507-512
- https://doi.org/10.1097/jcp.0b013e31814ce50d
Abstract
Extended-release naltrexone (XR-NTX) is a once-a-month injectable formulation that is Food and Drug Administration-approved for the treatment of alcohol dependence in patients able to abstain from alcohol before treatment initiation. This paper presents the results of an analysis of efficacy data from a subgroup of patients with 4 days or more of voluntary abstinence before treatment initiation (n = 82) on a wide range of drinking-related outcomes. In these patients, all of whom received counseling, the rate of abstinence was severalfold higher for XR-NTX 380 mg compared with placebo: median time to first drink was 41 days versus 12 days, respectively; rate of continuous abstinence at end of the study was 32% versus 11% (P = 0.02). Extended-release naltrexone 380 mg, compared with placebo, substantially increased time to first heavy drinking event (>180 days vs 20 days; P = 0.04) and decreased the median number of any drinking days per month by 90% (0.7 vs 7.2; P = 0.005) and heavy drinking days per month by 93% (0.2 days vs 2.9 days; P = 0.007). The XR-NTX 380 mg group also had more than twice as many responders compared with placebo (70% vs 30%; P = 0.006; responder defined as having no more than 2 heavy drinking days in any consecutive 28-day period) and experienced greater improvement in gamma-glutamyl transpeptidase levels (P = 0.03). Outcomes for XR-NTX 190 mg (n = 26) were generally intermediate, demonstrating a dose-response effect. In conclusion, XR-NTX 380 mg prolonged abstinence and reduced the number of heavy drinking days and drinking days in patients who were abstinent for as few as 4 days before treatment initiation.Keywords
This publication has 13 references indexed in Scilit:
- Combined Pharmacotherapies and Behavioral Interventions for Alcohol DependenceJama-Journal Of The American Medical Association, 2006
- Single‐ and Multiple‐Dose Pharmacokinetics of Long‐acting Injectable NaltrexoneAlcohol: Clinical and Experimental Research, 2006
- Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol DependenceJAMA, 2005
- A Pilot Evaluation of the Safety and Tolerability of Repeat Dose Administration of Long‐Acting Injectable Naltrexone (Vivitrex®) in Patients With Alcohol DependenceAlcohol: Clinical and Experimental Research, 2004
- The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002Drug and Alcohol Dependence, 2004
- Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic reviewAddiction, 2004
- Datapoints: Trends in Naltrexone Use Among Members of a Large Private Health PlanPsychiatric Services, 2004
- Understanding US addiction physicians' low rate of naltrexone prescriptionDrug and Alcohol Dependence, 2003
- Improving Naltrexone ResponseJournal of Addictive Diseases, 2000
- Alcohol dependence syndrome: Measurement and validation.Journal of Abnormal Psychology, 1982